Pharmaceutical Nanotechnology. Coordinator: Orienti

Nanoencapsulation of anticancer drugs in biocompatible materials endowed with specific affinity for tumor cells. Preparation and physico-chemical / functional evaluation of nanoformulations for biological drugs such as monoclonal antibodies and oligonucleotides.

Research themes

Increase of the therapeutic efficacy of naturally derived drugs and biological drugs through  delivery in nanoformulations characterized by controlled biodistribution.

Lab Members

Isabella Orienti , Full Professor (e-mail)

João Paulo Figueiró Longo -Associate Professor University of Brasília (external member)

Internship projects

1 internship project/academic year

Main publications

Lodeserto P, Rossi M, Blasi P, Farruggia G, Orienti I. (2022). “Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines.” Pharmaceutics 14(6):1215. doi: 10.3390/pharmaceutics14061215.

Orienti I, Farruggia G, Nguyen F, Guan P, Calonghi N, Kolla V, Chorny M, Brodeur GM. (2020) “Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor. “ Int J Nanomedicine 15:6873-6886. doi: 10.2147/IJN.S262032.

Orienti I, Nguyen F, Guan P, Kolla V, Calonghi N, Farruggia G, Chorny M, Brodeur GM. (2019) “A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.” Drug Des Devel Ther. 13:4305-4319. doi: 10.2147/DDDT.S221909.

Orienti I, Salvati V, Sette G, Zucchetti M, Bongiorno-Borbone L, Peschiaroli A, Zolla L, Francescangeli F, Ferrari M, Matteo C, Bello E, Di Virgilio A, Falchi M, De Angelis ML, Baiocchi M, Melino G, De Maria R, Zeuner A, Eramo A. (2019) “A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.” J Exp Clin Cancer Res. 38(1):373. doi: 10.1186/s13046-019-1383-9.

Orienti I, Francescangeli F, De Angelis ML, Fecchi K, Bongiorno-Borbone L, Signore M, Peschiaroli A, Boe A, Bruselles A, Costantino A, Eramo A, Salvati V, Sette G, Contavalli P, Zolla L, Oki T, Kitamura T, Spada M, Giuliani A, Baiocchi M, La Torre F, Melino G, Tartaglia M, De Maria R, Zeuner A. (2019) “A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis.” 10(7):529. doi: 10.1038/s41419-019-1775-y.